Stock VICO VICORE PHARMA HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up

All News Vicore Pharma Holding AB

Equities

VICO

SE0007577895

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
19.7 SEK +2.18% Intraday chart for Vicore Pharma Holding AB +2.60% +38.93%
May. 22 Transcript : Vicore Pharma Holding AB - Special Call
May. 20 Vicore Pharma Holding AB Announces Positive Final Results from the Phase 2a Air Trial Demonstrating Buloxibutid Improves Lung Function over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Increase of number of shares and votes in Vicore Pharma
AQ
Transcript : Vicore Pharma Holding AB - Special Call
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
AQ
Vicore Pharma Holding AB Announces Positive Final Results from the Phase 2a Air Trial Demonstrating Buloxibutid Improves Lung Function over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
CI
Vicore Expands and Strengthens its Board of Directors
AQ
Vicore Pharma Holding AB Announces Board Appointments
CI
Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)
AQ
Interim report January-March 2024
AQ
Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Vicore to Present at Upcoming April 2024 Investor Conferences
AQ
Vicore to Present at Upcoming Investor Conferences
AQ
Vicore to Present at Upcoming Investor Conferences
AQ
Vicore Pharma Holding AB Announces Maarten Kraan, as Board Member Declined Re-Election
CI
Notice of annual general meeting of Vicore Pharma Holding AB (publ)
AQ
Vicore Announces Presentations at the 2024 American Thoracic Society International Conference
AQ
Vicore publishes the Annual Report for 2023
AQ
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis
AQ
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis
CI
Year-end report 2023
AQ
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VICO Stock
  4. News Vicore Pharma Holding AB